Clinical outcomes of long‐acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real‐world data from the Spanish RELATIVITY cohort
HIV Medicine · 2026-01 · 27 (1) · 58-73
DOI: 10.1111/hiv.70114 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift HIV Medicine, online erschienen am 21.10.2025. Verfasst von Jesús Troya und 25 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Infanta Leonor, Madrid, Spain. Hauptthemen laut MEDLINE: HIV Infections, Rilpivirine, Pyridones, Anti-HIV Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
Long‐acting injectable cabotegravir and rilpivirine (LAI CAB + RPV) is an established maintenance strategy for people with HIV who are virologically suppressed, providing high efficacy and convenience in treatment. However, evidence in older adults (≥60 years), a growing and complex population, is limited.
Methods
We conducted an ambispective real‐world sub‐analysis of the Spanish RELATIVITY cohort, including people with HIV aged ≥60 years who initiated LAI CAB + RPV across 58 centres. Outcomes (virological suppression, safety, discontinuation and adherence) were compared with those
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Universitario Infanta Leonor, Madrid, Spain.
- Hospital Universitario La Paz, Madrid, Spain.
- Hospital Clínico Universitario de Valencia, Valencia, Spain.
- Hospital Universitario Puerta de Hierro, Madrid, Spain.
- Hospital Universitario 12 de Octubre, Madrid, Spain.
- Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
ORCID-Profile: Jesús Troya, Carmen Hidalgo, Francisco Fanjul, Luis Buzón
Zitieren
APA
Troya, J., Montes, M. L., Galindo, M. J., Santiago, A. D., Lagarde, M., Rodríguez, D., Rodríguez, A., Crussels, M. J., Torralba, M., Hidalgo, C., Fanjul, F., Soler, J. F., Gisbert, L., Díez, C., Pérez, D., Romero, A., Ferreira, E. M., Cabo, R., Rúiz-Alonso, N., …, & Buzón, L. (2026). Clinical outcomes of long‐acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real‐world data from the Spanish RELATIVITY cohort. HIV Medicine, 27(1), 58-73. https://doi.org/10.1111/hiv.70114
Vancouver
Troya J, Montes ML, Galindo MJ, Santiago AD, Lagarde M, Rodríguez D, et al. Clinical outcomes of long‐acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real‐world data from the Spanish RELATIVITY cohort. HIV Medicine. 2026;27(1):58-73. doi:10.1111/hiv.70114
BibTeX
@article{Troya2026,
author = {Troya, Jesús and Montes, María Luisa and Galindo, María José and Santiago, Alberto Díaz-de and Lagarde, María and Rodríguez, Daniel and Rodríguez, Adrián and Crussels, María José and Torralba, Miguel and Hidalgo, Carmen and Fanjul, Francisco and Soler, Josefa Francisco and Gisbert, Laura and Díez, Cristina and Pérez, Desiré and Romero, Alberto and Ferreira, Eva María and Cabo, Rebeca and Rúiz-Alonso, Noelia and Escrich, Cristina and Sepúlveda, María Antonia and Padilla, Sergio and Corte, Juan José and Pedrero-Tomé, Roberto and RELATIVITY Group, RELATIVITY Group and Buzón, Luis},
title = {Clinical outcomes of long‐acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real‐world data from the Spanish RELATIVITY cohort},
journal = {HIV Medicine},
year = {2026},
volume = {27},
number = {1},
pages = {58--73},
doi = {10.1111/hiv.70114}
}
EUVIMED